Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

Delayed Quote. Delayed  - 09/26 05:35:17 pm
36.475 EUR   -1.23%
09/23 MORPHOSYS : to Present at Upcoming Investor Conferences
09/19 MORPHOSYS : Lanthio Pharma Expands Management Team
09/12 MORPHOSYS : Appoints Four R&D Experts to its Newly Formed Scientific..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

MorphoSys AG : to Present at Three Investor Conferences in November

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/14/2011 | 03:05pm CEST

MorphoSys AG / MorphoSys to Present at Three Investor Conferences in November . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that management will present at three international investor conferences in November.

9th WestLB Deutschland Conference
Date:                          November 16, 2011 at 10:15am CET (09:15am GMT; 
                                  04:15am EST)
Venue:                        Frankfurt, Germany
Participants:                Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

Deutsches Eigenkapitalforum
Date:                          November 22, 2011 at 09:45am CET (08:45am GMT;
                                  03:45am EST)
Venue:                        Frankfurt, Germany
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

23rd Annual Piper Jaffray Healthcare Conference
Date:                          November 30, 2011 at 01:30pm EST (06:30pm GMT;
                                  07:30pm CET)
Venue:                        New York, USA
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate 
                                  Communications & IR

A PDF version of the Company presentation will be provided at www.morphosys.com/presentations:
http://www.morphosys.com/presentations. Links to the webcast, if available, are filed under www.morphosys.com/conference-calls:
http://www.morphosys.com/conference-calls.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company's AbD Serotec unit uses HuCAL and other technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Through its own development efforts and successful partnerships in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline:
http://www.morphosys.com/pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com:
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, arYla®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com:
mailto:investors@morphosys.com

Conference Announcement November:
http://hugin.info/130295/R/1563518/484733.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1563518

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
09/23 MORPHOSYS : to Present at Upcoming Investor Conferences
09/19 MORPHOSYS : Lanthio Pharma Expands Management Team
09/12 MORPHOSYS : Appoints Four R&D Experts to its Newly Formed Scientific Advisory Bo..
09/06 MORPHOSYS : Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine ..
08/29 MORPHOSYS : to Present at Upcoming Investor Conferences
08/18 MORPHOSYS : "Anti-CD38 Antibody and Lenalidomide Or Bortezomib for the Treatment..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
08/17 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
More news
Sector news : Biotechnology & Medical Research - NEC
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/21 MorphoSys (MPSYY) Presents at Bank of America Merrill Lynch 2016 Global Healt..
08/01 MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2016 Results - Earnings Call Trans..
08/01 MorphoSys AG 2016 Q2 - Results - Earnings Call Slides
08/01 MorphoSys AG reports H1'16 results
05/03 MorphoSys' (MPSYF) CEO Simon Moroney on Q1 2016 Results - Earnings Call Trans..
Advertisement
Financials (€)
Sales 2016 49,2 M
EBIT 2016 -64,6 M
Net income 2016 -50,7 M
Finance 2016 213 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 15,6x
EV / Sales 2017 14,7x
Capitalization 980 M
More Financials
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 58,3 €
Spread / Average Target 58%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-35.94%1 100
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results